Transformative Diagnostics



bioref


Next-Generation Therapies & Vaccines

Addressing large, unmet global markets with innovative proprietary products More »

Worldwide Production & Distribution

Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »

Strategic Investments

Identifying early-stage companies with potential to increase value for shareholders More »

Chairman’s Message

OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors and I would like to review several highlights.

 

  

 OPKO Completes Acquisition of Bio-Reference Laboratories.

 

 

OPKO Letter to Shareholders»

News & Events

more news »

OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD more »

OPKO Provides Update to Topline Data of Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults more »

OPKO'S GeneDx Extends Relationship with University of California Health for Genetic and Molecular Testing more »

Investors

read more »

OPKO Health is an opportunistic research and development company that targets large, high-growth markets.

 

 

FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease click here »